Navigation Links
New anti-inflammatory drugs pinch off reactive oxygen species at the source

Scientists at Emory University School of Medicine have identified a new type of anti-inflammatory compound that may be useful in treating a wide range of conditions, including neurodegenerative and autoimmune diseases. These compounds inhibit the enzyme Nox2, part of a family of enzymes responsible for producing reactive oxygen species (ROS).

The results were published Thursday in the journal Chemistry & Biology.

"Nox2 inhibitors could be valuable with many conditions where inflammation plays a role," says senior author David Lambeth, MD, PhD, professor of pathology and laboratory medicine at Emory University School of Medicine.

ROS and the Nox enzymes play vital roles in the immune and cardiovascular systems, but too much ROS leads to oxidative stress, linked with tissue damage and conditions such as stroke, heart failure and neurodegenerative diseases.

Antioxidants are supposed to absorb ROS, but many clinical studies examining antioxidants' benefits have been disappointing. Compounds that inhibit the Nox enzymes would stop ROS production at the source, rather than mop them up like antioxidants do.

"We are taking a completely different approach," says first author Susan Smith, PhD, Emory research assistant professor of pathology and laboratory medicine. "If a burst pipe is gushing water all over the basement, the first thing you need is a wrench to stop the water from flowing, instead of a mop."

The Nox inhibitors that were already available to researchers are not specific enough for one enzyme over another. Smith collaborated with research scientist Jaeki Min and colleagues at the Emory Chemical Biology Discovery Center and Emory Institute for Drug Development to screen for compounds that inhibit Nox2. In particular, they searched for compounds that interfere with assembly of the Nox2 enzyme rather than targeting the catalytic site.

The screen for compounds that inhibit Nox2 led to the identification of ebselen, a drug that has been tested previously in clinical trials in acute stroke and more recently, hearing loss. Previous researchers had thought that ebselen acted by another mechanism. Smith and Lambeth say their results do not conflict with earlier reports, and ebselen may have several modes of action depending on the concentration. Ebselen inhibited the Nox2 enzyme and to a lesser extent, Nox1, but not other Nox enzymes.

A side effect of Nox2 inhibition could be impairment of immune responses to bacteria and fungi, Lambeth says. One of Nox2's main functions in immune cells is to produce a toxic burst of ROS for killing bacteria and fungi.

People with an inherited deficiency in Nox2 develop chronic granulomatous disease (CGD), and are unable to fight off common infections. However, short-term or incomplete inhibition could have therapeutic effects without disabling antibacterial activity. CGD carriers who have reduced but residual Nox2 activity do not display symptoms.

Lambeth says the identification of ebselen is a starting point for refining drugs that target Nox2 and other Nox enzymes.

"This is just the tip of the iceberg," he says. "It's a good sign that ebselen is relatively non-toxic. Through medicinal chemistry, it should be possible to generate even more potent inhibitors, which could be candidates for drug development."

Contact: Quinn Eastman
Emory University

Related medicine news :

1. Not taking gastroprotective drugs prescribed with anti-inflammatory medicines
2. Trivedi Beef, LLC Announces Breakthrough Beef Industry Data without the use of Antibiotic Drugs, Hormones or Steroids
3. New drugs, new ways to target androgens in prostate cancer therapy
4. More Mental Health Woes in College Kids Who Abuse Prescription Drugs
5. American Kids Getting Fewer Prescription Drugs: Study
6. Depressed Teens Who Respond to Treatment Less Likely to Abuse Drugs
7. Doubling down on heart failure: Researchers discover new route to disease, and drugs to match
8. New federal disclosure law may have little impact on drugs prescribed
9. More Research Points to Long-Term Ills With Bone Drugs
10. New inflammation hormone link may pave way to study new drugs for Type 2 diabetes
11. Common Blood Pressure Drugs May Not Cut Colon Cancer Risk
Post Your Comments:
(Date:10/12/2015)... ... ... winner of the “Check-In and Win a Vacation to Hawaii” Facebook contest at Gold’s ... “I didn’t believe I could win a free vacation simply by checking in on Facebook ... gym and invest in my own health – and now I’m going to Hawaii.” , ...
(Date:10/12/2015)... Bloomingdale, Illinois (PRWEB) , ... October 12, 2015 ... ... not support the practice of hypnosis by individuals who lack professional education and ... offer hypnosis to the public for a variety of purposes such as: losing ...
(Date:10/12/2015)... Pittsburgh, PA (PRWEB) , ... October 12, 2015 , ... ... Or, perhaps, a cocktail umbrella one would find atop a drink in a tiki ... part of a clinical trial at Allegheny General Hospital (AGH) could potentially signal a ...
(Date:10/12/2015)... ... October 12, 2015 , ... ... leader in workforce resilience from EAP to crisis management, will present a session ... Wisconsin Dells, Wisconsin, Oct. 14-16, 2015. , FEI’s Chief Operating Officer Daniel Potterton ...
(Date:10/12/2015)... ... October 12, 2015 , ... SQM Group is proud ... contact channel benchmarking study. Be a part of this insightful and leading-edge ... customer experience, customer journey, contact channel execution and intelligence, workforce optimization, and tools ...
Breaking Medicine News(10 mins):
(Date:10/12/2015)... , October 12, 2015 ... research report "Spirometer Market by Product (Hand-held, Table-top, Desktop), Technology ... Homecare), Application, & Geography - Global Forecast to 2020", published ... 858.6 Million by 2020, at a CAGR of 9.8% from ... and 128 F igures spread th rough 187 ...
(Date:10/12/2015)... PUNE, India , October 12, 2015 /PRNewswire/ ... The Plague - Pipeline Review, H2 2015 ... helps strengthen plague R&D pipelines by identifying new ... products. . --> ... report on Plague pipeline spread across 62 pages, ...
(Date:10/12/2015)... 2015 Device usage in healthcare continues to ... these devices into existing clinical workflow. In response, Ergotron, ... mobility solutions, has launched the SV10 series of its ... wide array of laptops and tablets. In addition, one ... for Microsoft Surface and is compatible with all Surface ...
Breaking Medicine Technology: